Welcome to our dedicated page for Forian news (Ticker: FORA), a resource for investors and traders seeking the latest updates and insights on Forian stock.
Forian Inc. (Nasdaq: FORA) is a data processing and analytics company focused on the life sciences, healthcare and financial services industries. This news page aggregates company-issued announcements, financial updates and other disclosures so readers can follow how Forian’s data science driven information and analytics solutions evolve over time.
In its public communications, Forian highlights developments related to its healthcare information platform, clinical data lake and proprietary information products. News items include quarterly and annual financial results, where the company reports revenue, income or loss from continuing operations, Adjusted EBITDA and other financial measures, as well as commentary on its strategic priorities. These releases also describe changes in data sources, expansion of assets such as the Chronos™ data lake and the company’s efforts to differentiate its offerings for life sciences and healthcare customers.
Corporate and strategic announcements form another key category of Forian news. The company has announced the divestiture of BioTrack to focus on core healthcare and life sciences activities, the acquisition of Kyber Data Science to add advanced healthcare data analytics and machine learning capabilities for financial services clients, and a partnership with Databricks to make its Chartis™ product available through the Databricks Marketplace. Updates on governance and capital markets matters, including conference participation, changes in directors, accounting firm transitions and proposals related to redomiciliation and potential take-private transactions, are also disclosed through press releases and SEC-related communications.
Investors, analysts and industry participants can use this news feed to review Forian’s most recent earnings announcements, strategic transactions, product-related updates and governance developments. Regularly reviewing these items can provide context on how the company manages its large-scale healthcare data assets, expands its analytics capabilities and addresses both healthcare and financial services customer needs.
Forian Inc. will join the Russell 3000 Index effective June 28, 2021, following the annual reconstitution. This inclusion, which captures the 4,000 largest US stocks by market capitalization, means Forian is also part of the large-cap Russell 1000 or small-cap Russell 2000 Index. CEO Dan Barton highlighted this milestone emphasizes the company's innovation in healthcare and cannabis technology. Russell indexes influence $10.6 trillion in assets, making membership significant for investment management and institutional strategies.
Forian Inc. (NASDAQ: FORA) reported significant growth in its fiscal Q1 2021, achieving $1.6 million in revenue, a staggering 2331% increase from $66,667 in Q1 2020. The company incurred a net loss of $4.5 million, a 565% rise compared to the prior year. Adjusted EBITDA was negative $2.9 million versus negative $0.7 million in 2020. The quarter included 29 days of Helix Technologies operations following a strategic business combination, reinforcing Forian's position in the healthcare and cannabis sectors. Additionally, the company raised $12 million through PIPE financing.
Forian Inc. (Nasdaq:FORA) will announce its financial results for Q1 2021 on May 17, 2021, before market opening. The announcement will be followed by a conference call at 8:30 a.m. ET the same day. This session aims to discuss the company's financial performance in detail. Interested participants can register for the conference call starting May 11, 2021, and access the earnings release at forian.com/investors.
Forian Inc. (Nasdaq:FORA) announced a successful securities purchase agreement, raising $12 million through a private investment in public equity (PIPE) financing. The deal involves the sale of 1,191,743 shares at an average price of $10.21 per share. Directors, including Executive Chairman Max Wygod, purchased 560,461 shares at $11.33 each, while unaffiliated investors acquired 631,282 shares at $8.95, a 15% discount to the previous day's trading price. Proceeds will support data acquisition and general corporate purposes.